A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.
Also called NCT07625215
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 360 participants
- Sponsor
- Registry
-
NCT07625215 -
2025-523807-31-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Bulgaria, Germany, Hungary, Italy, Netherlands, Poland
- Registry status
- Recruiting
Technical summary
Registry record NCT07625215. Randomized; double masking; primary purpose treatment. Start 2026-09-01 (actual); primary completion 2030-05-16 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
- Acronym
- CARDIOVERT
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- BAY 3670549
- Intervention (Other)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct07625215- Content hash
6d03f18c0ba3b6fd3a1f3b1ed71912f57068494649c8b88986d0ab052b54e430